logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Top-line Results From Phase 3 Study Of Taltz

Eli Lilly and Company (LLY) reported top-line results from a phase 3 study on Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve. Taltz met the primary and all secondary endpoints, at both week 16 and week 52. The safety profile of Taltz was consistent with the prior Phase 3 studies of Talt.

Based on the data, the company plans to submit to regulatory authorities in 2019 for approval for nr-axSpA.

For comments and feedback contact: editorial@rttnews.com

Follow RTT